These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 21288571

  • 1. Polycythemia vera evolving into a rapidly progressive Ph-negative del(5q)-positive myeloproliferative neoplasm refractory to lenalidomide.
    Dasanu CA, Schwartz RA, Bauer F, Davis LK, Silver JS, Reale MA.
    Leuk Res; 2011 May; 35(5):e41-3. PubMed ID: 21288571
    [No Abstract] [Full Text] [Related]

  • 2. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.
    Santana-Davila R, Tefferi A, Holtan SG, Ketterling RP, Dewald GW, Knudson RA, Steensma DP, Chen D, Hoyer JD, Hanson CA.
    Leuk Res; 2008 Dec; 32(12):1927-30. PubMed ID: 18538839
    [Abstract] [Full Text] [Related]

  • 3. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies.
    Giagounidis AA, Germing U, Aul C.
    Clin Cancer Res; 2006 Jan 01; 12(1):5-10. PubMed ID: 16397017
    [Abstract] [Full Text] [Related]

  • 4. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
    Heise C, Carter T, Schafer P, Chopra R.
    Expert Rev Anticancer Ther; 2010 Oct 01; 10(10):1663-72. PubMed ID: 20942636
    [Abstract] [Full Text] [Related]

  • 5. A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
    Xu F, Li X, Chang C, He Q, Zhang Z, Zhang Q, Wu L.
    Leuk Res; 2009 Nov 01; 33(11):e199-202. PubMed ID: 19592091
    [No Abstract] [Full Text] [Related]

  • 6. The role of lenalidomide in the management of myelodysplasia with del 5q.
    Kelaidi C, Eclache V, Fenaux P.
    Br J Haematol; 2008 Feb 01; 140(3):267-78. PubMed ID: 18217896
    [Abstract] [Full Text] [Related]

  • 7. Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasms.
    Boiocchi L, Vener C, Savi F, Bonoldi E, Moro A, Fracchiolla NS, Iurlo A, Deliliers GL, Coggi G, Bosari S, Gianelli U.
    J Clin Pathol; 2011 Mar 01; 64(3):226-31. PubMed ID: 21217153
    [Abstract] [Full Text] [Related]

  • 8. Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification.
    Kvasnicka HM, Thiele J.
    Pathobiology; 2007 Mar 01; 74(2):63-71. PubMed ID: 17587877
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hematologic and cytogenetic response to lenalidomide in de novo acute myeloid leukemia with chromosome 5q deletion.
    Peñarrubia MJ, Silvestre LA, Conde J, Cantalapiedra A, Garcia Frade LJ.
    Leuk Res; 2009 Jun 01; 33(6):e8-9. PubMed ID: 19168219
    [No Abstract] [Full Text] [Related]

  • 11. Case of polycythemia vera concurrent with FIP1L1-PDGFRA-positive myeloproliferative neoplasm with eosinophilia.
    Alrwas A, Quesada JR, Marcos LA, Mehta SS, Shattuck BL, Nguyen ND, Juneja HS.
    Cancer Genet; 2012 Oct 01; 205(10):519-22. PubMed ID: 22944561
    [Abstract] [Full Text] [Related]

  • 12. Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.
    Göhring G, Lange K, Hofmann W, Nielsen KV, Hellström-Lindberg E, Roy L, Morgan M, Kreipe H, Büsche G, Giagounidis A, Schlegelberger B.
    Leukemia; 2012 Feb 01; 26(2):356-8. PubMed ID: 21799512
    [No Abstract] [Full Text] [Related]

  • 13. Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide.
    Eclache V, Da Rocha A, Le Roux G, Fenaux P.
    Haematologica; 2008 Feb 01; 93(2):315-6. PubMed ID: 18245660
    [Abstract] [Full Text] [Related]

  • 14. [Not Available].
    Bächli E, Gundelfinger M.
    Praxis (Bern 1994); 2017 Jul 01; 106(15):807-813. PubMed ID: 28745110
    [No Abstract] [Full Text] [Related]

  • 15. Chromosome abnormalities in the myeloproliferative disorders.
    Dewald GW, Wright PI.
    Semin Oncol; 1995 Aug 01; 22(4):341-54. PubMed ID: 7638632
    [No Abstract] [Full Text] [Related]

  • 16. Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion.
    Defina M, Rondoni M, Gozzetti A, Aprile L, Chitarrelli I, Fabbri A, Lauria F, Bocchia M.
    Br J Haematol; 2010 Feb 01; 148(3):483-4. PubMed ID: 19874309
    [No Abstract] [Full Text] [Related]

  • 17. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G, Giagounidis A, Büsche G, Kreipe HH, Zimmermann M, Hellström-Lindberg E, Aul C, Schlegelberger B.
    Ann Hematol; 2010 Apr 01; 89(4):365-74. PubMed ID: 19855965
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of lenalidomide in an sAML patient with del 5q relapsing after reduced-intensity allogeneic stem cell transplantation performed in complete remission.
    Adès L, Eclache V, Gardin C, Boehrer S, Leroux G, Martiat P, Fenaux P.
    Bone Marrow Transplant; 2010 Apr 01; 45(4):791-2. PubMed ID: 19718061
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q).
    Xiong B, Liu X, Zou P, Fan L, Chen W, Li W, Liu L.
    Leuk Res; 2010 Jul 01; 34(7):e169-72. PubMed ID: 20122730
    [No Abstract] [Full Text] [Related]

  • 20. Cytogenetic studies in Philadelphia chromosome-negative myeloproliferative disorders, particularly polycythaemia rubra vera.
    Lawler SD.
    Clin Haematol; 1980 Feb 01; 9(1):159-74. PubMed ID: 6768481
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.